|TABLE OF CONTENTSCluster's lifeOur member's newsSave the dateCalls for projectsAround our themes|
To end this month of May, we would like to thank all our members who participated to our General Assembly. You are the reason for the cluster's existence. Check back soon in video, the presentations of 10 of our 2018 new members!
In June, Lyonbiopôle will lead a delegation of 17 structures to the BIO International Convention 2019 in Philadelphia, USA.
Finally, register before June 14th for our Clinical Innovation Day and its "health data" and "clinical development" workshops.
The Lyonbiopole team.
|Lyonbiopole go along with 17 organizations to BIO international ConventionFrom June 3-6, 2019, Philadelphia will host the BIO International Convention, the major annual gathering the biotechnology community. Lyonbiopole, a European leading healthcare cluster based in Auvergne-Rhône-Alpes will attend this year with 17 organizations. [...]|
|BioTrinity MissionFor the 2nd consecutive year and with the support of the Auvergne-Rhône-Alpes Region, Lyonbiopole has invited 4 of its members to BIOTRINITY in order to help them in their fundraising efforts and their search for partners. In total, several hundred participants from the entire world have attended different plenary sessions, keynotes and roundtables, and have above all been able to schedule numerous one-to-one meetings with international investors as well as commercial and industrial partners.|
|China MissionIn partnership with Club CIC International and thanks to the support of the Auvergne-Rhône-Alpes Region, Lyonbiopole led a delegation of 4 members to Singapore and Shanghai (China) to support their Asiatic development. It was an opportunity for them to better understand the caracterisics of the Chinese and south east Asian markets and to meet investors and potential local partners.|
|5th Innovative Start-up DayThe 5th edition of Innovative Medtech Start-up Day organized by the SNITEM with the support of Lyonbiopole. This event brought together more than 1000 participants. Through several round tables, pitch and conferences, attendees had the opportunity to discuss about regulatory issues, market access and investments.|
|Biomed ISRAELLyonbiopole led a discovery mission in Israel, at MIXiii-Biomed. Lyonbiopole gain a 360 ° vision of local ecosystem actors in healthcare through B2B meetings and visit of the local actors (industrial, academic, clinicians, investors, incubators, clusters ...). Lyonbiopole, as the gateway of its ecosystem, has also promoted the strengths of Auvergne-Rhône-Alpes in the areas of biotech, medtech and nutrition-health.|
|General Assembly of LyonbiopoleThis privileged moment was an opportunity to present the past year and phase III results, and to reveal the main strategic axes of phase IV. We thank all the attendees and particulary the 10 new members of 2018 who pitched in front of this assemblee: Alphanosos , CFL biotech, Datamento, Deepsen, Dicartech, EusaPharma, ISARA, Molsid, Osivax et Santé-Net.|
|Lunch Break Partnering Low Balance Sheet FinancingAt the end of the month, we held the Lunch Break Partnering "Low Balance Sheet Financing" in partnership with our associate member BNP Paribas and BPI France. Both of them involved Project Managers specialized in Healthcare industries. The opportunity for the 20 participants to learn more about the bank financing in innovative companies. This intervention ended with the testimony of KERANOVA's managers.|
|S3martmed WebinarAs part of the European S3martMed project, Lyonbiopole and its partners organized this month a Webinar on the theme "3D printing for Medical devices", an exchange that allowed participants to discover innovative projects in Europe (including a team from Fraunhofer Institute about Biomaterials and the 3D FAB platform in Lyon). In parallel, the S3marMed partners are preparing their 1st networking event to be held on September 19 and 20 at the University hospital in Tubingen (Bade Wurtemberg). Registration will open in mid-June.|
|Focus onIxaltis is pleased to announce successful completion of the phase 2 of clinical development in urinary incontinence for its lead compound Litoxetine. [...]|
|May 2nd, 2019Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement||May 3th, 2019The European Lead Factory, Europe's largest collaborative drug discovery platform, continues its success story||May 6th, 2019Erytech proposes the appointment of Dr. Jean-Paul Kress as chairman of the board of directors|
|May 6th, 2019Co-tutelle PhD Proposals Program ECLAUSio||May 9th, 2019PDC*line Pharma obtains authorization to launch phase I/II||May 9th, 2019Biom'up granted FDA IDE approval for HEMOSNOW|
|May 15th, 2019ERYTECH announces FDA's authorization to proceed with phase 3 trial for Eryaspase in pancreatic cancer||May 15th, 2019GeNeuro confirms RAINBOW positive results||May 15th, 2019VALBIOTIS will present the results of the international Phase IIA clinical study of VALEDIA before 31 July 2019|
|May 16th, 2019CALIXAR announces the grant of the MemTrain||May 20th, 2019BIOTEM enters into collaboration with CALIXAR||May 23th, 2019MaaT Pharma receives three patents covering its biotherapeutic microbiome restoration platform|
|BIO International Convention 2019|
June 3th, 2019Clinical Innovation Day 2019
June 27th, 2019Nutrition and Health Assesses 2019 “Metabolic Health and Nutrition"
September 11th, 2019Germany MedTech Mission 2019
September 17th, 2019BIO Japan 2019 Mission
October 7th, 2019International Mission Health Nutrition - Dublin, Germany
October 14th, 2019SAVE THE DATE : Partnering Day 2019
October 15th, 2019Convention BIO-Europe 2019
November 11th, 2019
June 24th, 2019
July 2nd, 2019
August 26th, 2019
November 18th, 2019
See All events
EUROPE & INTERNATIONAL
Before June 5th, 2019
Before September 3th, 2019
Before September 12th, 2019
June 3th, 2019
November 5th, 2019
This email has been sent automatically to [[EMAIL_TO]]. Click here to unsubscribe.